Get the Stockscreener App
0.9135
1.73%
0.0155
Inflarx N V stock is traded at $0.9135, with a volume of 601.40K.
It is up +1.73% in the last 24 hours and up +8.14% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.898
Open:
$0.89
24h Volume:
601.40K
Relative Volume:
1.34
Market Cap:
$61.33M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.057
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+5.86%
1M Performance:
+8.14%
6M Performance:
-50.08%
1Y Performance:
-39.50%
1-Day Range:
$0.82
$0.9487
1-Week Range:
$0.82
$0.9499
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9135 | 61.81M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx N.V. Stock Approaches Key Moving AverageJuly 2025 Opening Moves & Verified Trade Idea Suggestions - thegnnews.com
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Real time social sentiment graph for InflaRx N.V.Analyst Upgrade & Growth Oriented Trading Recommendations - Newser
InflaRx N.V. stock chart pattern explained2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Regression analysis insights on InflaRx N.V. performanceJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Will InflaRx N.V. see short term momentumGap Down & Community Driven Trade Alerts - Newser
Detecting support and resistance levels for InflaRx N.V.Weekly Profit Summary & Risk Managed Investment Strategies - Newser
What makes InflaRx N.V. stock price move sharply2025 Price Momentum & Risk Managed Trade Strategies - Newser
How moving averages guide InflaRx N.V. tradingOil Prices & Short-Term High Return Ideas - Newser
Published on: 2025-08-19 14:22:07 - Newser
What momentum shifts mean for InflaRx N.V.Market Activity Recap & Accurate Intraday Trading Signals - Newser
Top chart patterns to watch in InflaRx N.V.Market Sentiment Report & Real-Time Market Sentiment Alerts - Newser
Is InflaRx N.V. stock reversal real or fakeJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
Combining machine learning predictions for InflaRx N.V.July 2025 Price Swings & High Win Rate Trade Tips - Newser
How high can InflaRx N.V. stock goMarket Growth Summary & Weekly Top Gainers Trade List - Newser
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
Is InflaRx N.V. Stock a Good Fit for Conservative InvestorsQuarterly Profit Review & Long-Term Capital Growth Strategies - Newser
XTX Topco Ltd Buys New Shares in InflaRx N.V. (NASDAQ:IFRX) - Defense World
What MACD signals say about InflaRx N.V.Options Play & Long-Term Capital Growth Ideas - Newser
Is it time to cut losses on InflaRx N.V.Quarterly Profit Summary & Consistent Growth Equity Picks - Newser
Is InflaRx N.V. benefiting from interest rate changesJuly 2025 Levels & Reliable Entry Point Trade Alerts - thegnnews.com
Key resistance and support levels for InflaRx N.V.Analyst Downgrade & Daily Volume Surge Signals - Newser
Predicting InflaRx N.V. trend using moving averagesJuly 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
Understanding InflaRx N.V.’s price movementExit Point & AI Driven Price Predictions - Newser
InflaRx N.V. stock momentum explained2025 Macro Impact & Low Risk Entry Point Tips - Newser
InflaRx N.V. stock daily chart insightsSector Rotation Outlook With Historical Summary - Newser
Sector ETF performance correlation with InflaRx N.V.Free Real Time Trade Opportunity Alerts - Newser
Sentiment analysis tools applied to InflaRx N.V.Daily Stock Movement Forecast with Accuracy - Newser
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):